Patents by Inventor Oleg Vechorkin

Oleg Vechorkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11299473
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 12, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Minh Nguyen, Alexander Sokolsky, Oleg Vechorkin, Qinda Ye, Wenqing Yao
  • Patent number: 11242343
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: February 8, 2022
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Publication number: 20220017521
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Application
    Filed: August 4, 2021
    Publication date: January 20, 2022
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • Publication number: 20210380581
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: January 7, 2021
    Publication date: December 9, 2021
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Publication number: 20210371425
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: April 23, 2021
    Publication date: December 2, 2021
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • Patent number: 11111247
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 7, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • Patent number: 11053215
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: July 6, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • Publication number: 20210171535
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 10, 2021
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
  • Publication number: 20210171518
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: November 16, 2020
    Publication date: June 10, 2021
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Patent number: 11014929
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • Publication number: 20210106588
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 14, 2020
    Publication date: April 15, 2021
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Publication number: 20210094934
    Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: September 9, 2020
    Publication date: April 1, 2021
    Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Qinda Ye, Wenqing Yao
  • Publication number: 20210094935
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 1, 2021
    Inventors: Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
  • Patent number: 10934288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Patent number: 10899755
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Publication number: 20210009582
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Application
    Filed: July 8, 2020
    Publication date: January 14, 2021
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • Publication number: 20210002288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
  • Patent number: 10800761
    Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: October 13, 2020
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
  • Publication number: 20200283434
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: February 10, 2020
    Publication date: September 10, 2020
    Inventors: Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Patent number: 10752635
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao